Comparison of Mindfulness Meditation Tools For College Students

September 25, 2019 updated by: Blair Johnson, University of Connecticut

Assisting University Students Self-Manage Stress: Comparison of Mindfulness Meditation Tools

The purpose of this study is to determine what tools best assist university students develop a personal meditation practice to self-manage stress. The two treatment conditions are 1) independent meditation using web-based tools and apps, and 2) independent meditation using web-based tools, apps and EEG-based neurofeedback. Outcomes of interest include acceptability, adherence, changes in mental health (i.e., anxiety, stress), physical health (i.e., sleep, inflammation), resilience, and level of commitment to further practice. Factors related to self-regulation (i.e., interoceptive awareness, self-esteem) will also be assessed as potential outcome moderators.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Unknown

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Investigators will conduct a randomized controlled trial to evaluate strategies for assisting students develop a personal meditation practice. All participants will attend a mindfulness orientation, then begin the four-week intervention. During the intervention period, the treatment group will practice EEG-neurofeedback-assisted meditation using the Muse device (Interaxon) at least eight times over the four-week intervention period, and also practice mindfulness meditation on their own using their choice of tools (e.g., apps, weblinks, breath). The active control group will mirror the treatment group but will not have access to the EEG-neurofeedback device.

After a sufficient number of students register for the study who meet eligibility requirements, they will be provided with an option to enroll online in the first wave of the study, if their schedule allows, or be placed on a waitlist. Subsequent waves will take place throughout the semester(s) to accommodate additional participants. Enrolled participants will be asked to complete the pre-workshop questionnaire packet online, and attend an orientation session. During the orientation session, participants will first sign a consent form, provide a baseline saliva sample, then learn the basic technique of mindfulness meditation with an experienced meditation instructor. The orientation will also briefly explain the potential benefits of meditation from a scientific perspective, and emphasize the importance of establishing a daily practice, with the mindset that even one minute counts. Participants will then be asked to meditate for 3 minutes wearing the EEG device in order to get a baseline EEG reading. Following the orientation workshop, participants will be randomly assigned and notified via email into either the active control or treatment group along with group-specific instructions, and the 4-week intervention period will commence. Upon completion of the 4-week intervention, participants will be asked to complete post-intervention questionnaires online, then provide post-test measures of saliva, EEG reading during a 3 minute meditation. Participants will be debriefed, and those in the active control group will be given the option to use the EEG-neurofeedback. Follow-up surveys will be emailed to participants at 3, 6 and 12 months to examine if participants continue their meditation practice.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
140

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • Storrs, Connecticut, United States, 06269
        • University of Connecticut

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • English literate, undergraduates and graduate students attending UConn ages 18 and above (unless they are registered with the participant pool), who agree with the initial terms, are willing to learn basic skills of mindfulness meditation, agree to practice meditating with assigned tools independently and feel able to adhere to the time commitment required for the study. Participants must not currently have a regular seated meditation practice (regular, meaning at least 1x per week).

Exclusion Criteria:

  • participants unable to adhere to the commitment required for the study will be excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental
independent meditation using web-based tools, apps, and EEG neurofeedback
Behavioral: Apps
Apps and weblinks to coach self-guided meditation.
Behavioral: EEG neurofeedback
Device provides feedback based on EEG readings.
Active Comparator: Active Control
independent meditation using web-based tools and apps
Behavioral: Apps
Apps and weblinks to coach self-guided meditation.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Depression, Anxiety, and Stress Scales-21
Time Frame: 5 weeks
(DASS-21; Lovibond & Lovibond, 1995): an abbreviated, 21-item, Likert-style scale to assess levels of distress on three subscales: depression, anxiety and stress, based on how one felt over the past week. The DASS-21 has been used in prior studies assessing the benefits of mindfulness in undergraduate students (Gallego et al., 2014). It consists of 21 items with seven items per subscale, scored on a four-point scale ranging from 0 = did not apply to me at all to 3 = applied to me very much or most of the time. The total score sums all items. Higher scores indicate higher levels of distress.
5 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Big Five personality
Time Frame: Baseline and 5 weeks
Big Five personality traits (Costa & McCrae, 1992), which are openness, conscientiousness, extraversion, agreeableness, and neuroticism. These factors have been used to understand the relationship between personality and various academic behaviors. Respondents rate each item on a five-point scale from "strongly disagree" to "strongly agree." This scale been used extensively in psychology research and has demonstrated good internal consistency, test-retest reliability, and validity (Costa & McCrae, 1992).
Baseline and 5 weeks
Pittsburgh Sleep Quality Index
Time Frame: Baseline and 5 weeks
Sleep quality will be assessed using the The Pittsburgh Sleep Quality Index (PSQI) (Buysse et al, 1989), a commonly used, validated and reliable measure of sleep quality.
Baseline and 5 weeks
Self-Regulation of Eating Scale
Time Frame: Baseline and 5 weeks
The Self-Regulation of Eating Behavior Questionnaire (SREBQ) is a short, Likert format questionnaire comprising of two dichotomous screener questions, one directional question to bring tempting foods to mind, and five Likert-format items assessing respondents' self-regulation of eating. The five Likert-format items span a five-point scale from 'Never' to 'Always'. The SREBQ has been shown to be reliable and valid (Kliemann et al., 2016).
Baseline and 5 weeks
MINDSENS (mindfulness)
Time Frame: Baseline and 5 weeks
a composite index consisting of selected items from two other mindfulness questionnaires (The Five Facet Mindfulness Questionnaire and Experiences Questionnaire) that showed the strongest response to practice.
Baseline and 5 weeks
Multidimensional Assessment of Interoceptive Awareness (MAIA)
Time Frame: Baseline and 5 weeks
Interoceptive self-awareness. Interoception refers to the signaling and perception of internal bodily sensations, which we will assess using the validated Multidimensional Assessment of Interoceptive Awareness (MAIA) (Mehling et. al., 2009 and 2012). The MAIA is a relatively new scale, with good validity and reliability in studies to date (Mehling et. al., 2009 and 2012; Bornemann et. Al., 2014).
Baseline and 5 weeks
Emotion Regulation Questionnaire (ERQ)
Time Frame: Baseline and 5 weeks
) (Gross & John, 2003). The ERQ assesses two specific emotion regulation strategies, suppression and reappraisal. The ERQ comprises 10 items (5 for suppression and 5 for reappraisal) rated from 1 (never do this) to 7 (always do this). The ERQ has demonstrated strong psychometric properties (Spaapen et al., 2014).
Baseline and 5 weeks
Experiences Questionnaire (decentering)
Time Frame: Baseline and 5 weeks
Decentering, a specific component of mindfulness related to learning how to separate from one's own thoughts and emotions, will be assessed with the Experiences Questionnaire (Fresco 2007).
Baseline and 5 weeks
Rosenberg (1965) self-esteem scale (RSES)
Time Frame: Baseline and 5 weeks
a self-esteem measure widely used in social-science research, with a scale of 0 (low) to 30 (high). It is a ten-item Likert-type scale with items answered on a four-point scale-from strongly agree to strongly disagree. It has been used extensively in research and has demonstrated good internal consistency, test-retest reliability, and validity.
Baseline and 5 weeks
Inflammatory cytokines (i.e., C-reactive protein, IL-6, and TNF-α)
Time Frame: Baseline and 5 weeks
Saliva samples will be obtained in-person, during pre- and post- assessments. Saliva samples will be stored for analysis to be performed at a later date, pending funding. Future analysis on saliva will be limited to assays on stress and health-related biomarkers and inflammatory cytokines (i.e., C-reactive protein, IL-6, and TNF-α). The "passive drool" method will be used to collect saliva samples, as described in Walsh et al., 2016.
Baseline and 5 weeks
State-Trait Anxiety Inventory (STAI)
Time Frame: Baseline and 5 weeks
Inventory aimed to measure one's awareness of their levels of both state and trait anxiety.
Baseline and 5 weeks
Connor-Davidson Resilience Scale (CD-RISC; Connor & Davidson, 2003)
Time Frame: Baseline and 5 weeks
The CD-RISC is a 25-item scale that measures the ability to cope with stress and adversity. Items include: "I am able to adapt when changes occur," "I tend to bounce back after illness, injury, or other hardships," and "I am able to handle unpleasant or painful feelings like sadness, fear, and anger." Respondents rate items on a scale from 0 ("not true at all") to 4 ("true nearly all the time"). A preliminary study of the psychometric properties of the CD-RISC in general population and patient samples showed it to have adequate internal consistency, test-retest reliability, and convergent and divergent validity (Connor & Davidson, 2003). This measure has been used in studies that assess resilience across the lifespan (Campbell-Sills et al., 2006).
Baseline and 5 weeks
Perceived Stress Scale-4 (PSS4)
Time Frame: Baseline and 5 weeks
(PSS4) is an abbreviated, 4-item Likert format scale designed to measure the degree to which situations in one's life are appraised as stressful (Cohen et al., 1983). The PSS is a validated, publicly available, and widely used psychological instrument for measuring stress. Each item asks the participant to appraise his or her feelings and thoughts using a 5-point Likert scale (0 = never, 4 = very often)
Baseline and 5 weeks

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Long-term Follow-up Survey
Time Frame: 1, 6, and 12 months following completion of the satisfaction follow-up
Simple 2 question survey will ask participants if they are still meditating, and if so, what tools they are using for assistance.
1, 6, and 12 months following completion of the satisfaction follow-up
Satisfaction with Mindfulness Tools
Time Frame: 5 weeks
After the completion of the 4-week trial, an 18-item instrument will be used to solicit participants' satisfaction with the meditation tools, as well as their feelings toward their meditation practice as a result of the intervention (i.e.,. confidence in ability, motivation to continue, and perceived benefits). The instrument was developed for this study and asks questions about perceived benefits of mindfulness meditation and intentions to continue practicing in the future.
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Connecticut

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Blair T. Johnson, PhD, University of Connecticut - BOT Distinguished Professor of Psychological Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 5, 2018

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 5, 2018

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
December 6, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 9, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 17, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 26, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 25, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • H17-224

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

De-identified individual participant data for primary and secondary outcome measures will be made available upon request.

IPD Sharing Time Frame

Data will be available after results have been published.

IPD Sharing Access Criteria

Data access requests will be reviewed and requestors will be required to sign a Data Access Agreement

IPD Sharing Supporting Information Type

  • Study Protocol
  • Informed Consent Form (ICF)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on Apps

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings